Pharma to Congress: We’re not cutting corners with Covid-19 vaccines
The companies developing vaccines for the novel coronavirus want to make one thing very clear: Just because the process is moving at unprecedented speed doesn’t mean the resulting products will be sloppily regulated.
At a House hearing yesterday, executives from five leading vaccine developers answered a few variations of the same question, unanimously insisting that the FDA showed no signs of bending its standards for the safety and efficacy of a future vaccine for Covid-19.
Where the executives differed, however, was on whether such a vaccine should be profitable. Two companies, AstraZeneca and Johnson & Johnson, promised to sell their future products on a not-for-profit basis, at least as long as the pandemic is an emergency. Pfizer and Moderna said they expected to make some amount of profit, while Merck said it was too early in the process to make any commitments on cost.
Read more.
At a House hearing yesterday, executives from five leading vaccine developers answered a few variations of the same question, unanimously insisting that the FDA showed no signs of bending its standards for the safety and efficacy of a future vaccine for Covid-19.
Where the executives differed, however, was on whether such a vaccine should be profitable. Two companies, AstraZeneca and Johnson & Johnson, promised to sell their future products on a not-for-profit basis, at least as long as the pandemic is an emergency. Pfizer and Moderna said they expected to make some amount of profit, while Merck said it was too early in the process to make any commitments on cost.
Read more.
No hay comentarios:
Publicar un comentario